Skip to main content
. Author manuscript; available in PMC: 2015 Apr 24.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):e1–e6. doi: 10.1097/QAI.0b013e318275741b

Table 3.

Moderate and severe adverse events by circumcision method*

Mogen (n=212) Gomco (n=203) Plastibell (n=215)

N Value N Value N Value P value
Bleeding
Yes 2 0.9% 6 3.0% 3 1.4% 0.298
No 210 99.1% 197 97.0% 212 98.6%
Infection
Yes 0 0.0% 1 0.5% 3 1.4% 0.226
No 212 100.0% 202 99.5% 212 98.6%
Cosmetic
Yes 8 3.8% 2 1.0% 1 0.5% 0.036
No 204 96.2% 201 99.0% 214 99.5%
Hospitalizations^
Yes 0 0.0% 2 1.0% 3 1.4% 0.291
No 212 100.0% 201 99.0% 212 98.6%
Any Moderate/Severe
Adverse Event 10 4.7% 9 4.4% 7 3.3% 0.746
Yes 202 95.3% 194 95.6% 208 96.7%
No
*

In infants with a six week follow up visit

^

Hospitalizations include infants with a bleeding, infection or cosmetic complication